CIK 0001740279 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
IN8BIO, INC.
Sign in to watch- Ticker
- INAB
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 825462585
- Phone
- (646) 600-6438
- Business address
- EMPIRE STATE BUILDING, 350 5TH AVENUE, SUITE 5330, NEW YORK, NY, 10118
- Former names
- Incysus Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 68 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-04-27 | McCall Patrick CHIEF FINANCIAL OFFICER | Returned to the company · Series B Warrants (right to buy) | −20,492 | 0 | ||
| 2025-04-27 | McCall Patrick CHIEF FINANCIAL OFFICER | Grant or award · Series B Warrants (right to buy) | +20,492 | 20,492 | ||
| 2025-04-27 | Roemer Alan S. Director | Returned to the company · Series A Warrants (right to buy) | −102,459 | 0 | ||
| 2025-04-27 | Roemer Alan S. Director | Grant or award · Series A Warrants (right to buy) | +102,459 | 102,459 | ||
| 2025-04-27 | Roemer Alan S. Director | Returned to the company · Series B Warrants (right to buy) | −102,459 | 0 | ||
| 2025-04-27 | Roemer Alan S. Director | Grant or award · Series B Warrants (right to buy) | +11,000 | 11,000 | ||
| 2025-04-27 | Roemer Alan S. Director | Grant or award · Series B Warrants (right to buy) | +91,459 | 91,459 | ||
| 2025-04-27 | Brandt Peter C. Director | Returned to the company · Series A Warrants (right to buy) | −81,967 | 0 | ||
| 2025-04-27 | Brandt Peter C. Director | Grant or award · Series A Warrants (right to buy) | +81,967 | 81,967 | ||
| 2025-04-27 | Brandt Peter C. Director | Returned to the company · Series B Warrants (right to buy) | −81,967 | 0 | ||
| 2025-04-27 | Brandt Peter C. Director | Grant or award · Series B Warrants (right to buy) | +81,967 | 81,967 | ||
| 2025-02-05 | McCall Patrick CHIEF FINANCIAL OFFICER | Grant or award · Employee Stock Option (right to buy) | +343,000 | 343,000 | ||
| 2025-02-05 | Lamb Lawrence EVP and CSO | Grant or award · Employee Stock Option (right to buy) | +306,750 | 306,750 | ||
| 2025-02-05 | Rochlin Kate Chief Operating Officer | Grant or award · Employee Stock Option (right to buy) | +338,950 | 338,950 | ||
| 2025-02-05 | Ho William Tai-Wei PRESIDENT AND CEO | Grant or award · Employee Stock Option (right to buy) | +912,450 | 912,450 | ||
| 2024-12-19 | Epperly Corinne Director | Grant or award · Stock Option (right to buy) | +37,655 | 37,655 | ||
| 2024-12-19 | Graff Jeremy R. Director | Grant or award · Stock Option (right to buy) | +47,697 | 47,697 | ||
| 2024-12-19 | Greenwood Luba Director | Grant or award · Stock Option (right to buy) | +39,449 | 39,449 | ||
| 2024-12-19 | FAIRBAIRN EMILY Director | Grant or award · Stock Option (right to buy) | +31,559 | 31,559 | ||
| 2024-12-19 | Whitfill Travis Director | Grant or award · Stock Option (right to buy) | +42,676 | 42,676 |
Page 4 of 9 · 179 trades